Kaiser Permanente's Genetic Database Is Boon to Medical Research
By Emily Anthes,
Bloomberg Businessweek
| 09. 25. 2014
Untitled Document
Over the past decade, Kaiser Permanente has spent more than $4 billion building the world’s largest private-sector collection of electronic health-care records. The data have become the cornerstone of a new scientific resource: a biobank that links the health records of more than 210,000 Kaiser members with samples of their DNA. The Oakland (Calif.)-based health network has teamed up with the University of California at San Francisco so scientists can use the collection to search for the genetic roots of diseases including glaucoma and prostate cancer.
Kaiser has 9.5 million enrollees in eight states and the District of Columbia, and members can see a wide variety of medical specialists without leaving the network. Every visit, lab test, prescription, and procedure is logged into a member’s electronic health record. This gives Kaiser an edge over other genomics projects, which besides collecting DNA samples must go through the expense and trouble of amassing information on subjects’ medical history. Last year biologist Craig Venter founded Human Longevity, with plans to sequence the genomes of as many as 100,000 people annually, and this summer,...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...